Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Q3 2025 value amounting to -$10.9 million.

  • Insight Molecular Diagnostics' Net Income towards Common Stockholders rose 1955.83% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 12211.93%. This contributed to the annual value of -$61.0 million for FY2024, which is 198615.86% down from last year.
  • As of Q3 2025, Insight Molecular Diagnostics' Net Income towards Common Stockholders stood at -$10.9 million, which was up 1955.83% from -$9.7 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders peaked at $4899.0 during Q1 2023, and registered a low of -$45.2 million during Q4 2022.
  • In the last 5 years, Insight Molecular Diagnostics' Net Income towards Common Stockholders had a median value of -$9.7 million in 2022 and averaged -$13.6 million.
  • Per our database at Business Quant, Insight Molecular Diagnostics' Net Income towards Common Stockholders soared by 10004.76% in 2023 and then plummeted by 19064909.17% in 2024.
  • Quarter analysis of 5 years shows Insight Molecular Diagnostics' Net Income towards Common Stockholders stood at -$35.9 million in 2021, then fell by 25.97% to -$45.2 million in 2022, then surged by 85.21% to -$6.7 million in 2023, then tumbled by 402.87% to -$33.6 million in 2024, then soared by 67.72% to -$10.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$10.9 million for Q3 2025, versus -$9.7 million for Q2 2025 and -$6.7 million for Q1 2025.